About Medytox
Medytox is a publicly listed company based in Seoul (South Korea) founded in 2000. Botulinum toxins, synthetic drugs, supplements, and medical devices are developed. The company has 776 employees. Its chief executive, as recorded, is Chung Hyun-ho. Its website medytox.com draws about 88 thousand monthly visits. Medytox offers products and services including Meditoxin, Innotox, Neuramis, and Coretox. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Medytox Co., Ltd.
Company details
Medytox has developed a botulinum toxin for medical aesthetics therapeutic applications. The product, Meditoxin, a botulinum toxin type A marketed under trade names Neuronox, INNOTOX Coretox. These products are used for the treatments of muscle spasticity, foot deformities, Benign essential blepharospasm globular wrinkles. Also developed Hyaluronic Acid Filler (branded as Neuramis Potenfill) to the treatment of facial wrinkles and physical recovery. Also developed medical devices for tissue coagulation injecting applications. The company is also developing the pipeline of biodrugs, medical devices, synthetic drugs health supplements.
- Headquarters Seoul, South Korea
- Employees 776
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website medytox.com
- Social LinkedIn YouTube
- Legal Name Medy-Tox Inc.
- Annual Revenue$171.23 M (USD)8.17as on Dec 31, 2025
- Net Profit$11.49 M (USD)-2.13as on Dec 31, 2025
- EBITDA$25.36 M (USD)-9.05as on Dec 31, 2025
- Employee Count776
Products & Services of Medytox
Medytox offers a comprehensive portfolio of products and services, including Meditoxin, Innotox, Neuramis, and Coretox.
Botulinum toxin for aesthetic and therapeutic injections.
Liquid formulation for wrinkle treatment and muscle disorders.
Filler for facial volume enhancement and skin rejuvenation.
Toxin product for medical and cosmetic applications.
Apps and channels of Medytox
its YouTube channel 메디톡스 Medytox has 1.21K subscribers and 30 videos.
Videos from Medytox
The most watched videos on Medytox's YouTube channel, 메디톡스 Medytox (1.21K subscribers). Click a video to play it here.
More on 메디톡스 Medytox.
People of Medytox
1 people are tracked at Medytox (1 in leadership); the tracked headcount is 776.
| Name | Role | Group |
|---|---|---|
Chung Hyun-ho | CEO | Leadership |
Complete people profiles for Medytox
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Medytox
Medytox is a publicly listed company on the KRX with ticker symbol 086900 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jan 2009
- Listed onKOSDAQ: 86900
- Listed entityMedy-Tox Inc.
- Exchange sectorHealth technology
- ISINKR7086900008
- Share price65,800.00 KRW (+3.62% on the day) · 2026-10-14
- Market capitalisation417,750,694,036.00 KRW
- Price to earnings28.6
- EPS (diluted, trailing year)2,299.60 KRW
- Dividend yield1.89%
- Volume (last session)24,182
Financials of Medytox
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 247.29B KRW | 16.59B KRW | 36.62B KRW |
| 2024 | 228.62B KRW | 16.95B KRW | 40.26B KRW |
| 2023 | 221.12B KRW | 9.76B KRW | 32.65B KRW |
| 2022 | 195.10B KRW | 37.01B KRW | 61.75B KRW |
| 2021 | 184.87B KRW | 94.15B KRW | 51.39B KRW |
Detailed financial statements for Medytox
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Medytox
The website of Medytox (medytox.com) receives about 87.7K visits a month and ranks #303,807 among all websites worldwide, #248 in Biotechnology and Pharmaceuticals.
- Monthly visits87.7K
▲ 24.3% vs previous month
- Unique visitors10.4K
per month
- Global rank#303,807
among all websites
- Category rank#248
Health · Biotechnology and Pharmaceuticals
- Bounce rate16%
- Pages per visit16.3
- Average visit13 min 47 sec
- DevicesDesktop 74% · Mobile 26%
Websites whose visitors overlap most with Medytox. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| yuyu.co.kr | 100% | 8.4K | #2,459,299 | View details | |
| medigatenews.com | 68% | #143,063 | View details | ||
dailymedi.com | dailymedi.com | 66% | #145,758 | – | |
| hitnews.co.kr | 62% | #146,502 | View details | ||
yakup.com | yakup.com | 59% | #118,603 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Medytox
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medytox
Complete news archive for Medytox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medytox
Medytox was founded in 2000.
Medytox is headquartered in Seoul, South Korea.
Chung Hyun-ho is the CEO of Medytox, as recorded in our data.
Medytox has 776 employees.
Annual revenue of Medytox is $171.23M as on Dec 31, 2025.
Medytox has developed a botulinum toxin for medical aesthetics therapeutic applications. The product, Meditoxin, a botulinum toxin type A marketed under trade names Neuronox, INNOTOX Coretox. These products are used for the treatments of muscle spasticity, foot deformities, Benign essential blepharospasm globular wrinkles. Also developed Hyaluronic Acid Filler (branded as Neuramis Potenfill) to the treatment of facial wrinkles and physical recovery. Also developed medical devices for tissue coagulation injecting applications. The company is also developing the pipeline of biodrugs, medical devices, synthetic drugs health supplements.
Medytox offers Meditoxin, Innotox, Neuramis, and Coretox.
Yes, Medytox is publicly traded on KRX under the ticker symbol 086900.
Medytox operates through Medytox Co., Ltd..